» Articles » PMID: 32623359

Changing Risk Factors for Hepatocellular Carcinoma in Hyperendemic Regions in the Era of Universal Hepatitis B Vaccination

Overview
Publisher Elsevier
Specialties Oncology
Public Health
Date 2020 Jul 6
PMID 32623359
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background: LongAn, Guangxi, was the first county in China to implement universal childhood hepatitis B virus (HBV) immunization. We aimed to determine its long-term effects in preventing hepatocellular carcinoma (HCC) 32 years after the immunization programme was launched.

Methods: Information on HCC deaths for LongAn and its neighbouring county, BinYang (where universal hepatitis B vaccination was not started till 2002), were obtained from the national mortality surveillance system. The data were analysed using Poisson regression.

Results: The overall age-adjusted mortalities of HCC in LongAn and BinYang during 2017-2018 were 53.3/100,000 and 45.4/100,000, respectively. The mortality of males aged 20-29 years in LongAn, who were vaccinated at birth, was lower (2.7/100,000, 95%CI 0.8-4.5) than that of males in BinYang, who were not vaccinated (4.7/100,000, 95%CI 3.2-6.3). In LongAn, the HCC mortality in adults aged 20-29 years declined significantly from 7.9/100,000 (95%CI 4.4-11.4) in 2004 to 1.4/100,000 (95%CI 0.4-2.4) in 2017-2018 (χ = 5.554, p = 0.018). Among those vaccinated at birth, the HCC mortality in mountainous areas, where dietary exposure to aflatoxins is more common, is higher (9.0/100,000, 95%CI 4.5-13.5) than in low-lying areas (6.5/100,000, 95%CI 3.6-9.4) (χ = 0.2393, p = 0.618).

Conclusion: Immunization of infants against HBV has reduced their risk of developing HCC as children and young adults but could not prevent all cases of HCC, suggesting that the major risk factor for HCC in hyperendemic regions is shifting from HBV to other factors. Additional prevention strategies for HCC will be needed in the future.

Citing Articles

Hepatic Artery Infusion Chemotherapy Sequential Hepatic Artery Embolization Combined with Operation in the Treatment of Recurrent Massive Hepatocellular Carcinoma Achieved Pathological Complete Response: A Case Report.

Chen J, Liao X, Wu Y, Ou S, Qin W, Yang C Pharmgenomics Pers Med. 2023; 16:949-958.

PMID: 37933333 PMC: 10625750. DOI: 10.2147/PGPM.S426791.


Low host immune pressure may be associated with the development of hepatocellular carcinoma: a longitudinal analysis of complete genomes of the HBV 1762T, 1764A mutant.

Jiang Z, Chen Q, Jia H, Wang X, Zhang L, Huang X Front Oncol. 2023; 13:1214423.

PMID: 37681020 PMC: 10481955. DOI: 10.3389/fonc.2023.1214423.


Hepatic Resection for Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of 7226 Patients.

Molinari M, Kaltenmeier C, Samra P, Liu H, Wessel C, Klem M Ann Surg Open. 2023; 2(2):e065.

PMID: 37636554 PMC: 10455059. DOI: 10.1097/AS9.0000000000000065.


Prognosis after hepatic resection of patients with hepatocellular carcinoma related to non-alcoholic fatty liver disease: meta-analysis.

Su J, Deng Z, Teng Y, Koh Y, Zhang W, Zheng M BJS Open. 2023; 7(1).

PMID: 36802244 PMC: 9939291. DOI: 10.1093/bjsopen/zrac167.


Massive Hepatocellular Carcinoma with Situs Inversus Totalis Achieved a Complete Response Following Camrelizumab Plus Apatinib and Combined with Two-Stage Hepatectomy: A Case Report.

Wu Y, Ou S, Liao X, Han C, Yang C, Qin W Pharmgenomics Pers Med. 2023; 16:111-120.

PMID: 36785780 PMC: 9921441. DOI: 10.2147/PGPM.S376596.